The FDA has not approved a stem-cell therapy specifically for male infertility as a licensed product. Investigational testicular stem-cell or MSC protocols are registered with the NIH but remain unapproved. The EMA likewise has not granted a marketed male-infertility-specific stem-cell product. Assisted reproductive technology (IVF, ICSI) remains the FDA-established standard for male-factor infertility. Testosterone replacement, when indicated, is FDA-approved for hypogonadism but does not address underlying spermatogenic failure. Patients should distinguish investigational protocols from unproven fertility clinics offering direct-to-consumer stem-cell treatments.
Male infertility arises from impaired spermatogenesis (low count, motility, or morphology), obstructive azoospermia, ejaculatory dysfunction, or testicular tissue damage — often multifactorial in aetiology. Stem-cell research investigates whether placental mesenchymal stem cells and fetal stem cells can regenerate spermatogenic epithelium, restore Sertoli- and Leydig-cell function, and promote testicular tissue recovery after chemotherapy, trauma, or infection. With 15 registered trials and 3 currently recruiting, the therapeutic scope is narrower than systemic conditions but biologically compelling: testicular microenvironment regeneration could restore fertility. Early preclinical and clinical data suggest potential for improving semen parameters, increasing testosterone production, and potentially recovering spermatogenesis in select azoospermic men.
Am I a candidate? → · Male Infertility: full overview → · Male Infertility cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估